Optimal Therapeutic Strategy for Non-small Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor

Optimal Therapeutic Strategy for Non-small Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor

Blog Article

Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in non-small cell lung cancer (NSCLC) patients, it is still controversial about how to combine EGFR-TKI STRESS-FX STRESS FORMULA with chemotherapy and other targeted drugs.We have made a summary on the current therapeutic models of EGFR-TKI combined with chemotherapy/bevacizumab in this review and aimed to Mains Power Lead find the optimal therapeutic strategy for NSCLC patients with EGFR mutation.